Open AccessThe Effect of Cisplatin-Etoposide Chemotherapy on Platelet Parameters in Lung Cancer Patients
Author(s) -
Oğuz Bilgi,
Bülent Karagöz,
Ahmet Alacacıoğlu,
Tolga Tunçel,
Alpaslan Özgün,
Levent Emirzeoğlu,
Emin Gökhan Kandemir
Publication year - 2013
Publication title -
disease and molecular medicine
Language(s) - English
Resource type - Journals
ISSN - 2147-6748
DOI - 10.5455/dmm.20130326023112
Subject(s) - medicine , etoposide , cisplatin , lung cancer , chemotherapy , oncology , platelet
The aim of this study was to investigate the effect of cisplatin etoposide chemotherapy on platelet indices in advanced stage lung cancer patients. Twenty advanced stage lung cancer patients who received cisplatin and etoposide chemotherapy and 35 healthy subjects were enrolled. The platelet indices (platelet count, mean platelet volume (MPV), plateletcrit (Pct) and platelet distribution width (PDW)) and other blood count parameters were recorded in baseline, before second cycle and after sixth cycle of chemotherapy. In baseline analysis, white blood cell count, but not other blood parameters, were different in patient group compared with control group,. After six cycles of chemotherapy, PDW values were elevated than baseline analysis in lung cancer patients. Other platelet parameters were not changed after chemotherapy. This study showed that MPV, platelet count, or Pct don't change after cisplatin-etoposide chemotherapy in lung cancer patients. [Dis Mol Med 2013; 1(2.000): 35-38